Patrys Limited Price (PAB.AX)

Stock Price

Low: Year Low
High: Year High

Market Cap

Fetching Data...

Enterprise Value

Fetching Data...

Fetching Data...

Shares Outstanding

2,055,750,235

(0.0169)%

Community Sentiment 0 votes
↑ 0% ↓ 0%

Description

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; an... Read More

Sector: Healthcare

  • Previous Close Fetching Data...
  • Range $0.002-0.01
  • Market Cap 4.11M
  • Enterprise Value No Data
  • Avg Volume Fetching Data...
  • P/E Ratio Fetching Data...
  • Dividend Yield Fetching Data...

Industry: Biotechnology

  • ceo: Dr. James A. Campbell B.Sc., MBA, Ph.D.
  • IPO Date: July, 13, 2007
  • Country: AU
  • Currency: AUD
  • Headquaters: Melbourne, VIC
  • Employees: 15

- Revenue from each product or segment:

Product or Segment Value: % - Total Last 3Y:
news-img

- Revenue by Region

Product or Segment Value: % - Total Last 3Y:
news-img
8 New Orders
close
Theme Customizer

Customize your theme

close

Theme variation